A review of the abuse potential assessment of atomoxetine: A nonstimulant medication for attention-deficit/hyperactivity disorder

Psychopharmacology

Volumn 226, Issue 2, 2013, Pages 189-200

  Upadhyaya, Himanshu P ^a,b,g   Desaiah, Durisala ^a   Schuh, Kory J ^a   Bymaster, Frank P ^c   Kallman, Mary J ^d   Clarke, David O ^a   Durell, Todd M ^a   Trzepacz, Paula T ^a   Calligaro, David O ^a   Nisenbaum, Eric S ^a   Emmerson, Paul J ^a   Schuh, Leslie M ^e   Bickel, Warren K ^f   Allen, Albert J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Covance Laboratories ^*  (United States)

^e St Vincent Bariatric Center of Excellence   (United States)

^f VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Abuse potential; ADHD; Atomoxetine (Strattera ); Nonstimulant

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; COCAINE; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; HYPNOTIC AGENT; METHYLPHENIDATE; MORPHINE; MU OPIATE RECEPTOR; NISOXETINE; NORADRENALIN TRANSPORTER; PLACEBO; SEDATIVE AGENT; TRIAZOLAM;

ATTENTION DEFICIT DISORDER; DRUG ABUSE; DRUG APPROVAL; DRUG DEPENDENCE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELF ADMINISTRATION; HAPLORHINI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ABUSE; LOCOMOTION; NERVE STIMULATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROBIOLOGY; NEUROTOXICITY; NONHUMAN; PRESYNAPTIC NERVE; PREVALENCE; PRIORITY JOURNAL; RECEPTOR AFFINITY; REINFORCEMENT; REVIEW; RODENT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ADDICTIVE; DRUG-SEEKING BEHAVIOR; HUMANS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROPYLAMINES; PROTEIN BINDING; RECEPTORS, NEUROTRANSMITTER; SUBSTANCE-RELATED DISORDERS;

EID: 84877153072     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-2986-z     Document Type: Review

References (89)

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
2. Barkley RA, Fischer M, Smallish L, Fletcher K (2002) The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 111:279-289
3. Bergman J, Madras BK, Johnson SE, Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates. III Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251:150-155
4. Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN (2000) Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacology (Berlin) 153:67-84
5. Berman SM, Kuczenski R, McCracken JT, London ED (2009) Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry 14:123-142
6. Biederman J, Wilens T, Mick E, Faraone SV, Weber W, Curtis S, Thornell A, Pfister K, Jetton JG, Soriano J (1997) Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 36:21-29
7. Bredeloux P, Dubuc I, Costentin J (2007) Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br J Pharmacol 150:711-719
8. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
9. Chase TD, Carrey N, Brown RE, Wilkinson M (2005) Methylphenidate regulates c-fos and fosB expression in multiple regions of the immature rat brain. Brain Res Dev Brain Res 156:1-12
10. Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ (1996) [3H]nisoxetine - a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 35:63-70
11. Darvesh AS, Carroll RT, Geldenhuys WJ, Gudelsky GA, Klein J, Meshul CK, Van der Schyf CJ (2011) In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery. Expert Opin Drug Discov 6:109-127
12. Di Chiara G, Tanda GL, Frau R, Carboni E (1992) Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers. Neurochem Int 20(Suppl):231S-235S
13. Dragunow M, Faull R (1989) The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods 29:261-265
14. Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104-113
15. Garland EJ (1998) Intranasal abuse of prescribed methylphenidate. J Am Acad Child Adolesc Psychiatry 37:1242-1243
16. Garnock-Jones KP, Keating GM (2010) Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs 24:85-88
17. Gasior M, Bergman J, Kallman MJ, Paronis CA (2005) Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology 30:758-764
18. Gatley SJ, Pan D, Chen R, Chaturvedi G, Ding YS (1996) Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 58:231-239
19. Graham D, Langer SZ (1992) Advances in sodium-ion coupled biogenic amine transporters. Life Sci 51:631-645
20. Greydanus DE, Pratt HD, Patel DR (2007) Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. Dis Mon 53:70-131
21. Hechtman L (2000) Assessment and diagnosis of attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:481-498
22. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE (2002) Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149-156
23. Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ (2008) Abuse potential assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 95:140-146
24. Johanson CE, Barrett JE (1993) The discriminative stimulus effects of cocaine in pigeons. J Pharmacol Exp Ther 267:1-8
25. Johanson CE, Schuster CR (1975) A choice procedure for drug reinforcers: cocaine and methylphenidate in the rhesus monkey. J Pharmacol Exp Ther 193:676-688
26. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2008) Monitoring the future national survey results on drug use, 1975-2007. Volume II: college students and adults ages 19-45. National Institute on Drug Abuse, US Department of Health and Human Services, Bethesda, MD
27. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2009) Monitoring the Future national survey results on drug use, 1975-2008. Volume II: college students and adults ages 19-50 (NIH Publication No. 09-7403). National Institute on Drug Abuse, US Department of Health and Human Services, Bethesda, MD
28. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2011) Monitoring the Future national survey results on drug use, 1975-2010. Volume II: college students and adults ages 19-50. Institute for Social Research, The University of Michigan, Ann Arbor
29. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2012) Monitoring the Future national results on adolescent drug use: overview of key findings, 2011. Institute for Social Research, The University of Michigan, Ann Arbor
30. Jones S, Kornblum JL, Kauer JA (2000) Amphetamine blocks long-term synaptic depression in the ventral tegmental area. J Neurosci 20:5575-5580
31. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A 102:3495-3500
32. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716-723
33. Kleven MS, Anthony EW, Woolverton WL (1990) Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 254:312-317
34. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T (2010) Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 114:259-270
35. Kollins SH (2007) Abuse potential of medications used to treat attention deficit/hyperactivity disorder (ADHD). Am J Addict 16(suppl 1):35-42
36. Koob GF (1992) Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 654:171-191
37. Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037
38. Kuczenski R, Segal DS (1999) Dynamic changes in sensitivity occur during the acute response to cocaine and methylphenidate. Psychopharmacology (Berlin) 147:96-103
39. Lile JA, Stoops WW, Durell TM, Glaser PE, Rush CR (2006) Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol 14:136-147
40. Lin JS, Hou Y, Jouvet M (1996) Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 93:14128-14133
41. Massello W III, Carpenter DA (1999) A fatality due to the intranasal abuse of methylphenidate (Ritalin). J Forensic Sci 44:220-221
42. Mazei MS, Pluto CP, Kirkbride B, Pehek EA (2002) Effects of catecholamine uptakeblockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res 936:58-67
43. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901
44. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120
45. Molina BS, Pelham WE Jr (2003) Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 112:497-507
46. Morgan JI, Curran T (1990) Inducible proto-oncogenes of the nervous system: their contribution to transcription factors and neuroplasticity. Prog Brain Res 86:287-294
47. Murnane KS, Howell LL (2011) Neuroimaging and drug taking in primates. Psychopharmacology 216:153-171
48. Nicholson KL, Balster RL, Golembiowska K, Kowalska M, Tizzano JP, Skolnick P, Basile AS (2009) Preclinical evaluation of the abuse potential of the analgesic bicifadine. J Pharmacol Exp Ther 330:236-248
49. Novak SP, Kroutil LA, Williams RL, Van Brunt DL (2007) The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2:32
50. Parran TV Jr, Jasinski DR (1991) Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med 151:781-783
51. Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319:237-246
52. Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, Caldarone B (2010) Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav 95:449-456
53. Pontieri FE, Tanda G, Di Chiara G (1995) Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad Sci U S A 92:12304-12348
54. Pristupa ZB, Wilson JM, Hoffman BJ, Kish SJ, Niznik HB (1994) Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol 45:125-135
55. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223
56. Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066
57. Rowlett JK, Platt DM, Yao WD, Spealman RD (2007) Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys. J Pharmacol Exp Ther 321:1135-1143
58. Rush CR, Essman WD, Simpson CA, Baker RW (2001) Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol 21:273-286
59. Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE (2002) Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J Neurosci 22:8705-8710
60. Sasaki JE, Tatham TA, Barrett JE (1995) The discriminative stimulus effects of methamphetamine in pigeons. Psychopharmacology (Berlin) 120:303-310
61. Shekim WO, Asarnow RF, Hess E, Zaucha K, Wheeler N (1990) A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry 31:416-425
62. Simpson D, Plosker GL (2004) Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64:205-222
63. Smoot LC, Boothby LA, Gillett RC (2007) Clinical assessment and treatment of ADHD in children. Int J Clin Pract 61:1730-1738
64. Spealman RD (1995) Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 275:53-62
65. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695
66. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ (2002) Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140-1147
67. Substance Abuse and Mental Health Services Administration (2006) Results from the 2005 National Survey on Drug Use and Health: national findings. Office of Applied Studies, US Department of Health and Human Services, Rockville, MD
68. Substance Abuse and Mental Health Services Administration (2007) Drug Abuse Warning Network, 2005: national estimates of drug-related emergency department visits. Office of Applied Studies, US Department of Health and Human Services, Rockville
69. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258
70. Terry P, Witkin JM, Katz JL (1994) Pharmacological characterization of the novel discriminative stimulus effects of a low dose of cocaine. J Pharmacol Exp Ther 270:1041-1048
71. The National Center on Addiction and Substance Abuse at Columbia University (2007) Wasting the best and the brightest: substance abuse at America's colleges and universities. http://www.casacolumbia.org/absolutenm/ articlefiles/380-Wasting%20the%20Best%20and%20the%20Brightest.pdf. Accessed 9 Dec 2009
72. Tidey JW, Bergman J (1998) Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. J Pharmacol Exp Ther 285:1163-1174
73. Upadhyaya HP (2007) Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry 68(Suppl 11):23-30
74. Upadhyaya HP, Rose K, Wang W, O'Rourke K, Sullivan B, Deas D, Brady KT (2005) Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol 15:799-809
75. Upadhyaya HP, Kroutil LA, Deas D, Durell TM, Van Brunt DL, Novak SP (2010) Stimulant formulation and motivation for nonmedical use of prescription attention-deficit/hyperactivity disorder medications in a college-aged population. Am J Addict 19:569-577
76. Volkow ND, Swanson JM (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160:1909-1918
77. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827-830
78. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325-1331
79. Volkow ND, Wang G, Fowler JS Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:RC121
80. Wee S, Woolverton WL (2004) Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend 75:271-276
81. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D (2004) Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol 24:30-35
82. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T (1997) Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 185:475-482
83. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S (2008a) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47:21-31
84. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR, Atomoxetine ADHD/SUD Study Group (2008b) Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 96:145-154
85. Wilens TE, Adler LA, Tanaka Y, Xiao F, D'Souza DN, Gutkin SW, Upadhyaya HP (2011) Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Curr Med Res Opin 27:2309-2320
86. Wilson MC, Hitomi M, Schuster CR (1971) Psychomotor stimulant self administration as a function of dosage per injection in the rhesus monkey. Psychopharmacologia 22:271-281
87. Yano M, Steiner H (2005) Topography of methylphenidate (ritalin)-induced gene regulation in the striatum: differential effects on c-fos, substance P and opioid peptides. Neuropsychopharmacology 30:901-915
88. Zhang L, Barrett JE (1991) Imipramine as a discriminative stimulus. J Pharmacol Exp Ther 259:1088-1093
89. - currents in rat thalamic reticular and relay neurons. J Neurophysiol 78:2280-2286